Invivyd

Performance

About Invivyd

Invivyd develops antibody-based therapies to rapidly counter evolving viral threats, focusing on potent monoclonal antibodies and a proprietary platform to address infectious diseases. The company’s pipeline targets serious viral diseases, with initial emphasis on COVID-19 and expansion to other high-need indications such as influenza, aiming to provide protective or therapeutic options that outperform natural immunity. Headquartered in the United States, Invivyd emphasizes science-driven development and partnerships to advance medicines that can adapt to virus evolution.